Ophthalmology – Ocular Hypertension

Basics

Description

Ocular hypertension (OHT) refers to consistently elevated intraocular pressure (IOP) in an eye with:

• Open anterior chamber angles
• No glaucomatous optic nerve damage
• No glaucomatous retinal nerve fiber layer loss
• No corresponding visual field defect
• No secondary ocular cause explaining the elevated IOP

Historically, OHT has often been defined as:

IOP >21 mmHg

However, 21 mmHg is a statistical threshold rather than a strict biologic cutoff.

The key distinction is:

Ocular hypertension = elevated IOP without glaucoma damage.

⸻

Epidemiology

Ocular hypertension is relatively common.

Estimated prevalence among adults older than 40 years is approximately:

4–7%

Only a proportion of patients with OHT eventually develop primary open-angle glaucoma.

⸻

Clinical Importance

OHT itself does not mean that glaucoma is present.

However:

Elevated IOP is the most important modifiable risk factor for developing primary open-angle glaucoma.

Management therefore focuses on determining:

• How high the individual patient’s risk is
• Whether preventive treatment is justified
• How closely the patient should be monitored

⸻

Risk of Conversion to Glaucoma

The landmark Ocular Hypertension Treatment Study (OHTS) identified several major predictors of progression from OHT to primary open-angle glaucoma.

Important risk factors include:

• Increasing age
• Higher baseline IOP
• Larger vertical cup-to-disc ratio
• Higher visual field pattern standard deviation
• Thinner central corneal thickness

The greater the number and severity of these factors, the greater the risk of conversion.

⸻

Central Corneal Thickness

Central corneal thickness is particularly important.

Thin cornea

A thin cornea may:

• Cause Goldmann applanation tonometry to underestimate IOP
• Be associated with a higher independent risk of glaucoma development

Thick cornea

A thick cornea may:

• Produce a higher measured IOP
• Make the apparent ocular hypertension less concerning in some patients

However:

There is no universally reliable formula for mathematically “correcting” IOP according to corneal thickness.

CCT should be interpreted as part of the overall risk profile.

⸻

Additional Risk Considerations

Other factors that may influence the decision to treat include:

• Strong family history of glaucoma
• African ancestry
• Long life expectancy
• Progressive increase in optic nerve cupping
• Disc hemorrhage
• Very high untreated IOP
• Thin cornea
• Suspicious OCT changes
• Reduced ability to attend reliable follow-up

⸻

Genetics

There is no single genetic marker that defines ocular hypertension.

OHT and primary open-angle glaucoma likely share a complex polygenic susceptibility.

Family history remains clinically useful even when molecular testing is not performed.

⸻

Pathophysiology

The exact reason some patients tolerate elevated IOP without optic nerve damage while others develop glaucoma is incompletely understood.

Important factors probably include differences in:

• Lamina cribrosa anatomy
• Optic nerve susceptibility
• Ocular blood flow
• Connective tissue properties
• Retinal ganglion cell resilience
• IOP magnitude and fluctuation

OHT may therefore be considered a risk state, not a disease with established neural injury.

⸻

Etiology

Primary ocular hypertension has no identifiable secondary cause.

Before making the diagnosis, exclude:

• Angle closure
• Pigment dispersion
• Pseudoexfoliation
• Uveitis
• Steroid response
• Ocular trauma
• Previous surgery
• Neovascularization
• Lens-related secondary glaucoma

⸻

Associated Conditions

OHT is associated primarily with:

• Increased risk of primary open-angle glaucoma
• Thick or thin central corneal thickness affecting interpretation of IOP

Some patients have no other ocular or systemic abnormality.

⸻

Diagnosis

OHT is a diagnosis of exclusion.

The patient must have elevated IOP but no demonstrable glaucomatous structural or functional damage.

⸻

History

Patients are usually:

Asymptomatic

Ask about:

• Previous IOP measurements
• Family history of glaucoma
• Steroid use
• Ocular trauma
• Previous ocular surgery
• Uveitis
• Migraine
• Sleep apnea
• Systemic hypertension
• Diabetes
• Medication history

⸻

Visual Symptoms

OHT itself does not usually cause:

• Pain
• Redness
• Visual field loss
• Reduced visual acuity

Symptoms suggest another diagnosis or a complication.

⸻

Examination

Intraocular Pressure

Elevated IOP should be confirmed on more than one occasion whenever practical.

Important considerations include:

• Time of day
• Measurement technique
• Corneal thickness
• Corneal biomechanics
• Patient squeezing
• Breath-holding
• Measurement error

⸻

Diurnal Variation

IOP varies throughout the day.

A patient with apparently mild OHT may have higher IOP outside usual clinic hours.

Repeated measurements at different times may occasionally be useful when:

• IOP is highly variable
• Optic nerve findings are suspicious
• Progression occurs despite apparently acceptable readings

⸻

Gonioscopy

Gonioscopy is essential.

OHT should have:

• Open angles
• No significant peripheral anterior synechiae
• No secondary angle abnormality

Gonioscopy helps exclude:

• Chronic angle closure
• Pigment dispersion
• Pseudoexfoliation
• Angle recession
• Neovascularization
• Inflammatory abnormalities

⸻

Optic Nerve Examination

The optic nerve should show no definite glaucomatous damage.

Assess:

• Cup-to-disc ratio
• Vertical cupping
• Neuroretinal rim thickness
• Rim notching
• Disc hemorrhage
• RNFL defects
• Inter-eye asymmetry

⸻

Suspicious Optic Nerve

Findings such as:

• Focal rim thinning
• Inferotemporal or superotemporal notching
• RNFL wedge defect
• Disc hemorrhage

raise concern that the patient may already have:

Early glaucoma rather than isolated OHT.

⸻

Optical Coherence Tomography

OCT should assess:

• Peripapillary RNFL
• Macular ganglion cell complex
• Ganglion cell–inner plexiform layer
• Optic nerve head

In true OHT, structural testing should remain within expected normal limits and stable over time.

Serial OCT is more useful than a single scan.

⸻

Optic Disc Photography

Baseline optic disc photographs are valuable for detecting future change.

They can document:

• Cup enlargement
• Rim thinning
• New disc hemorrhage
• RNFL changes

⸻

Visual Field Testing

Standard automated perimetry is required to establish that there is no functional glaucomatous loss.

Typical baseline testing includes:

• 24-2
• 24-2C depending on availability

If central damage is suspected, a:

• 10-2 visual field

may be useful.

⸻

Pachymetry

Central corneal thickness should be measured in essentially all patients with OHT.

This helps with:

• IOP interpretation
• Risk stratification

Thin CCT is an important predictor of conversion to glaucoma.

⸻

Differential Diagnosis

Important alternatives include:

• Primary open-angle glaucoma
• Secondary open-angle glaucoma
• Chronic angle-closure glaucoma
• Steroid-induced ocular hypertension
• Pigmentary glaucoma
• Pseudoexfoliative glaucoma
• Uveitic glaucoma
• Angle-recession glaucoma

⸻

Ocular Hypertension vs Primary Open-Angle Glaucoma

Ocular Hypertension

• Elevated IOP
• Open angle
• No optic nerve damage
• No RNFL loss
• No visual field defect

Primary Open-Angle Glaucoma

• Open angle
• Characteristic optic nerve/RNFL damage
• Corresponding visual field loss may be present
• IOP may be elevated or normal

⸻

Treatment Principles

Not every patient with OHT requires treatment.

Management may consist of:

• Observation
• Medical therapy
• Laser trabeculoplasty

The decision depends on the estimated risk of developing glaucoma.

⸻

OHTS Findings

The Ocular Hypertension Treatment Study showed that lowering IOP reduces the risk of conversion to glaucoma.

At approximately 5 years:

• Untreated patients developed glaucoma at roughly 9.5%
• Treated patients developed glaucoma at roughly 4.4%

Therefore:

IOP reduction approximately halved the relative risk of developing glaucoma.

⸻

Important Interpretation

The absolute benefit of treatment is greatest in:

High-risk patients

Low-risk patients may reasonably be observed because many never develop glaucoma.

⸻

Initial Target IOP

In OHTS, treatment aimed for approximately:

• At least 20% reduction from baseline IOP
• IOP of approximately 24 mmHg or lower

This is a useful starting concept, but modern targets should be individualized.

⸻

When Observation Is Reasonable

Observation is often appropriate when:

• IOP is only mildly elevated
• CCT is relatively thick
• Optic nerve is healthy
• OCT is normal
• Visual fields are normal
• Patient is young but low risk
• Reliable follow-up is possible

⸻

When Treatment Is Favored

Treatment should be considered when there is:

• Very high IOP
• Thin CCT
• Large cup-to-disc ratio
• Suspicious optic nerve appearance
• Strong family history
• Older age
• Long expected lifetime risk
• Progressive structural change
• High calculated OHTS risk
• Difficulty ensuring reliable follow-up

⸻

Selective Laser Trabeculoplasty

Selective laser trabeculoplasty (SLT) is now an important first-line treatment option.

Advantages include:

• Effective IOP reduction
• Avoidance or delay of daily medication
• Minimal systemic effects
• Repeatability in selected patients

It may be used:

• As primary treatment
• As adjunctive treatment

⸻

Prostaglandin Analogs

Common first-line topical agents include:

• Latanoprost
• Travoprost
• Bimatoprost
• Tafluprost

Advantages include:

• Strong IOP-lowering effect
• Once-daily dosing
• Minimal systemic adverse effects

⸻

Beta-Blockers

Examples include:

• Timolol
• Betaxolol

They are effective but should be used cautiously in patients with:

• Asthma
• COPD
• Bradycardia
• Heart block
• Significant hypotension

They are no longer automatically preferred over prostaglandin analogs or SLT as first-line therapy.

⸻

Topical Carbonic Anhydrase Inhibitors

Examples include:

• Dorzolamide
• Brinzolamide

These may be used as:

• Monotherapy
• Adjunctive therapy

⸻

Alpha-2 Agonists

Example:

• Brimonidine

Useful as adjunctive therapy but may cause:

• Allergy
• Fatigue
• Dry mouth

⸻

Rho Kinase Inhibitors

Modern options include:

• Netarsudil

They may provide additional IOP lowering, particularly when target pressure is not reached with other therapies.

⸻

Oral Carbonic Anhydrase Inhibitors

Examples include:

• Acetazolamide
• Methazolamide

These are not routinely used long term for uncomplicated OHT because of systemic adverse effects.

They may be used temporarily in selected cases with very high IOP.

⸻

Surgery

Incisional glaucoma surgery is rarely required for isolated ocular hypertension.

Procedures such as:

• Trabeculectomy
• Tube shunt

are generally reserved for patients who:

• Develop definite glaucoma
• Have extremely high uncontrolled IOP
• Fail medical and laser treatment

⸻

MIGS

Minimally invasive glaucoma surgery is generally not performed solely for uncomplicated OHT unless:

• Cataract surgery is being performed
• There is another compelling indication

Treatment burden should be proportional to disease risk.

⸻

Follow-Up

Follow-up frequency should be individualized according to:

• IOP
• CCT
• Optic nerve appearance
• OCT findings
• Visual field findings
• Risk of conversion

⸻

High-Risk OHT

Patients at higher risk may be followed approximately every:

3–6 months

with periodic:

• IOP measurements
• Optic nerve examination
• OCT
• Visual field testing

⸻

Low-Risk Stable OHT

Once stability is established, lower-risk patients may often be followed every:

6–12 months

depending on individual circumstances.

⸻

Patient Monitoring

Monitor for the first evidence of conversion to glaucoma:

• Progressive cup enlargement
• Neuroretinal rim thinning
• RNFL loss
• Ganglion cell loss
• Reproducible glaucomatous field defect
• Disc hemorrhage

⸻

Risk Calculators

OHTS/EGPS-based risk calculators can estimate the approximate risk of developing glaucoma using factors such as:

• Age
• IOP
• CCT
• Vertical cup-to-disc ratio
• Visual field PSD

They can help guide treatment decisions but should not replace clinical judgment.

⸻

Patient Education

Patients should understand that:

• Ocular hypertension is not the same as glaucoma.
• Many patients never develop optic nerve damage.
• Elevated IOP increases future glaucoma risk.
• Regular monitoring is necessary even when vision is normal.
• Treatment can reduce the risk of developing glaucoma.

⸻

Medication Adherence

For patients receiving drops:

• Use medications consistently.
• Learn proper instillation.
• Consider punctal occlusion to reduce systemic absorption.
• Report ocular allergy or systemic adverse effects.

Poor adherence may make apparent treatment failure difficult to interpret.

⸻

Prognosis

The overall prognosis is excellent when patients are appropriately monitored.

Most patients with OHT do not rapidly develop glaucoma.

Risk varies greatly between individuals.

⸻

OHTS Prognosis

At approximately 5 years:

• About 9.5% of untreated participants developed primary open-angle glaucoma.
• About 4.4% of treated participants developed glaucoma.

Thus, most patients remained free of glaucoma during that period even without treatment.

This supports a risk-based rather than automatic treatment approach.

⸻

Complications

The principal complication is:

Conversion to primary open-angle glaucoma

with subsequent:

• RNFL loss
• Optic nerve damage
• Visual field loss
• Permanent visual impairment if uncontrolled

Treatment-related complications may include:

• Ocular surface disease
• Medication allergy
• Systemic drug effects
• Laser-related inflammation or transient IOP spike

⸻

Ophthalmology Pearls

• Ocular hypertension = elevated IOP without glaucomatous optic nerve, RNFL, or visual field damage.
• An IOP above 21 mmHg is a statistical threshold, not a biologic definition of glaucoma.
• OHT is a risk state, not established optic neuropathy.
• The major OHTS predictors of conversion are older age, higher IOP, larger vertical cup-to-disc ratio, higher visual field PSD, and thinner CCT.
• Thin corneas increase risk and may cause IOP underestimation; thick corneas may cause higher measured IOP.
• Do not use a simplistic numerical formula to “correct” IOP for corneal thickness.
• Gonioscopy, pachymetry, OCT, optic nerve examination, and visual fields are fundamental to diagnosis.
• Not every patient with ocular hypertension needs treatment.
• OHTS showed that treatment reduced 5-year conversion from approximately 9.5% to 4.4%.
• A useful initial treatment concept is roughly 20% IOP reduction, adjusted according to the patient’s risk.
• SLT or a prostaglandin analog are appropriate first-line options in many patients when treatment is indicated.
• Incisional glaucoma surgery is rarely appropriate for uncomplicated OHT.
• Long-term management should be based on risk of conversion and evidence of structural or functional progression.